Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated…
Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, announced the completion of a $100 million Series…
Read More...
Read More...